BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:06 pm EST
Share
BioAdaptives, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.015649 million compared to USD 0.003337 million a year ago. Net loss was USD 0.013061 million compared to USD 0.276325 million a year ago.
For the nine months, sales was USD 0.021364 million compared to USD 0.013192 million a year ago. Net loss was USD 0.444165 million compared to USD 0.867293 million a year ago.
BioAdaptives, Inc. manufactures and distributes natural plant and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Its product line for humans includes PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore. It also markets the Lung Flute and PrimiLungs products in its Lung Armor packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the device. Its animal products include an Equine All-in-One and Equine All-In-One Plus formulation, which it markets to trainers, horse owners and boarding stables, and a Canine All-in-One.